Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.71 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481127 | 0.88 | CYP3A4 (0.74) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL13033285 | 0.88 | CYP3A4 (0.74) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17481128 | 0.87 | CYP3A4 (0.82) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL13462781 | 0.85 | QPCT (0.64) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17481134 | 0.84 | CYP3A4 (0.78) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17483163 | 0.84 | CYP3A4 (0.78) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL12999042 | 0.83 | QPCT (1.00) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17481129 | 0.83 | QPCT (0.66) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17483288 | 0.83 | QPCT (0.66) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL16384621 | 0.83 | QPCT (0.66) | QPCTQPCTLCYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100292432-A1 | POLYMERS FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010127154-A1 | POLYMERS FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127159-A2 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | QPCT 2353/4885QPCTL 2159/4885CYP3A4 4858/4885 |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | QPCT 229/4885QPCTL 2009/4885CYP3A4 13/4885 |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | QPCT 2353/4885QPCTL 2159/4885CYP3A4 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.